Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes

被引：65

作者：

Kim, JJ

Nottingham, LK

Wilson, DM

Bagarazzi, ML

Tsai, A

Morrison, LD

Javadian, A

Chalian, AA

Agadjanyan, MG

Weiner, DB ^{[1
]}

机构：

[1] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA

[2] Univ Penn, Dept Chem Engn, Philadelphia, PA 19104 USA

[3] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA

[4] Univ Penn, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA

[5] Coulston Fdn, Alamogordo, NM 88310 USA

来源：

VACCINE | 1998年 / 16卷 / 19期

关键词：

DNA vaccination; CTL; immune responses; CD80; CD86; co-stimulatory molecules; AIDS/HIV-1;

D O I：

10.1016/S0264-410X(98)00177-7

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

DNA immunization has been investigated as a potential immunization strategy against infectious diseases and cancer. To enhance a DNA vaccine's ability to induce CTL response in vivo, we co-administered CD80 and CD86 expression cassettes along with HIV-1 immunogens. This manipulation resulted in a dramatic increase in MHC class I-restricted and CD8+ T-cell-dependent CTL responses in both mice and chimpanzees. This strategy of engineering vaccine producing cells to be more efficient T-cell activators could be an important tool for optimizing antigen-specific T-cell-mediated immune responses in the pursuit of more rationally designed vaccines and immune therapies. (C) 1998 Elsevier Science Ltd. All rights reserved.

引用

页码：1828 / 1835

页数：8

共 28 条

[1]

AGADJANYAN MG, 1994, VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P47

[2] An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV [J].